Stock Analysis

Three Stocks Estimated To Be Below Fair Value In September 2025

As the U.S. stock market navigates a period of cautious optimism, with indices like the S&P 500 and Nasdaq reaching new highs before experiencing slight pullbacks, investors are closely watching the Federal Reserve's upcoming interest rate decision. In this environment of fluctuating economic indicators and consumer resilience, identifying stocks that are potentially undervalued can offer unique opportunities for growth. A good stock in such conditions often combines strong fundamentals with a price that is perceived to be below its intrinsic value, making it an attractive consideration for those seeking to capitalize on market inefficiencies.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In The United States

NameCurrent PriceFair Value (Est)Discount (Est)
VTEX (VTEX)$4.20$8.3849.9%
Pinnacle Financial Partners (PNFP)$94.65$186.5949.3%
Phibro Animal Health (PAHC)$39.01$77.6749.8%
Northwest Bancshares (NWBI)$12.31$24.4149.6%
Niagen Bioscience (NAGE)$9.49$18.6449.1%
Investar Holding (ISTR)$22.62$44.9249.6%
Horizon Bancorp (HBNC)$16.13$31.8049.3%
Glaukos (GKOS)$82.35$161.3749%
Exact Sciences (EXAS)$52.94$103.1848.7%
AGNC Investment (AGNC)$10.13$20.2349.9%

Click here to see the full list of 192 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Repligen (RGEN)

Overview: Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems globally, with a market cap of approximately $6.40 billion.

Operations: Repligen generates revenue from its Medical Products segment, totaling $673.96 million.

Estimated Discount To Fair Value: 28.0%

Repligen is trading at 28% below its estimated fair value of US$166.36, presenting a potential undervaluation based on discounted cash flow analysis. The company forecasts revenue growth of 14.4% per year, outpacing the broader U.S. market's average growth rate of 9.7%. Recent executive changes aim to strengthen financial oversight, while strategic partnerships and updated guidance underscore efforts to enhance operational efficiency and drive profitability over the next three years.

RGEN Discounted Cash Flow as at Sep 2025
RGEN Discounted Cash Flow as at Sep 2025

Roku (ROKU)

Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market cap of approximately $13.84 billion.

Operations: Roku's revenue is primarily generated from two segments: Devices, contributing $595.16 million, and Platform, which accounts for $3.80 billion.

Estimated Discount To Fair Value: 39.3%

Roku's current trading price of US$97.91 is significantly below its estimated fair value of US$161.33, suggesting potential undervaluation based on cash flow analysis. Despite a forecasted revenue growth rate of 10.2% per year, which surpasses the U.S. market average, Roku's return on equity is expected to remain low at 7.4%. The recent launch of innovative products like the Aurzen Roku TV Smart Projector could bolster future cash flows and profitability prospects.

ROKU Discounted Cash Flow as at Sep 2025
ROKU Discounted Cash Flow as at Sep 2025

CareTrust REIT (CTRE)

Overview: CareTrust REIT is a self-administered, publicly-traded real estate investment trust focused on owning, acquiring, developing, and leasing seniors housing and healthcare-related properties with a market cap of $7.65 billion.

Operations: The company's revenue primarily stems from its investments in healthcare-related real estate assets, totaling $373.42 million.

Estimated Discount To Fair Value: 41.2%

CareTrust REIT's stock, priced at US$34.13, trades significantly below its estimated fair value of US$58.02, highlighting potential undervaluation based on cash flows. The company's earnings are projected to grow by 22.36% annually over the next three years, outpacing the U.S. market average growth rate of 15.4%. However, shareholders have faced substantial dilution recently and dividends remain inadequately covered by earnings despite a recent affirmation of a quarterly dividend payment.

CTRE Discounted Cash Flow as at Sep 2025
CTRE Discounted Cash Flow as at Sep 2025

Summing It All Up

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:RGEN

Repligen

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Excellent balance sheet with reasonable growth potential.

Advertisement